Development of Churg‑Strauss syndrome with severe multiple mononeuropathy after leukotriene receptor antagonist treatment in one of the monozygotic twins with asthma

Targońska-Stępniak, Bożena; Majdan, Maria; Haberek, Grzegorz; Papuć, Ewa; Wnukowska, Kinga

doi:10.20452/pamw.835

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second example is a pair of twins, both affected by asthma and treated with the same drug (leukotriene receptor antagonists, by instance, suspected to cause EGPA): one twin developed EGPA and the other did not [224]. Nevertheless, the search for risk factors or susceptibility continues to be an object of interest.…”

Section: Egpa (Formerly Churg-strauss Syndrome): Familial Clustering mentioning

confidence: 99%

Genetic Basis of Myocarditis: Myth or Reality?

et al. 2020

View full text Add to dashboard Cite

Section: Egpa (Formerly Churg-strauss Syndrome): Familial Clustering mentioning

confidence: 99%

Genetic Basis of Myocarditis: Myth or Reality?

et al. 2020

View full text Add to dashboard Cite

“…In the 1990s, soon after the introduction of cysteinyl receptor antagonists to the market, their association with Churg-Strauss syndrome was reported. [27][28][29][30][31] It could, however, be a result of a reduction in the dose of systemic glucocorticosteroids during antileukotriene treatment of asthma in the course of a not yet diagnosed Churg-Strauss syndrome. Zileuton has a hepatotoxic effect.…”

mentioning

confidence: 99%

Antileukotriene drugs in the treatment of asthma

Mastalerz¹,

Kumik²

2010

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Antileukotriene medications that have been implemented into clinical practice of bronchial asthma and allergic rhinitis include specific leukotriene receptor antagonists (montelukast, zafirlukast, pranlukast) and leukotriene bio synthesis inhibitors (zileuton). The current GINA (Global Initiative for Asthma) guidelines, the PRACTALL (Practicing Allergology) report on asthma treatment in children, and ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations classify antileukotriene therapeutic agents as a group of drugs controlling the course of the disease. However, inhaled glucocorticosteroids still remain the first-line treatment in chronic asthma. According to current guidelines, antileukotriene drugs are recommended as alternative treatment to low-dose inhaled glucocorticosteroids in the second level of asthma severity and as complementary treatment to inhaled and/or oral glucocorticosteroids, starting from the third level of asthma severity. Recently, clinical efficacy of antileukotriene drugs has been suggested in the treatment of isolated allergic rhinitis, chronic cough in the course of asthma, as a sole symptom of the disease, and as the therapy for episodes of wheezing caused by viral infections.

show abstract

Endothelial dysfunction in patients with eosinophilic granulomatosis with polyangiitis

et al. 2018

View full text Add to dashboard Cite

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis associated with asthma and eosinophilia. Endothelial dysfunction has been well documented in other types of vasculitis but not in EGPA. Thirty patients (10 men and 20 women) diagnosed with EGPA and remaining in a remission, and 58 controls (24 men and 34 women) matched for age, sex, and body mass index, were enrolled in the study. We assessed each participants for typical risk factors of cardiovascular diseases and measured serum levels of vascular cell adhesion molecule-1 (VCAM-1), interleukin 6 (IL-6), and thrombomodulin. We also measured flow-mediated dilatation (FMD) of the brachial artery and intima-media thickness (IMT) of the common carotid artery using ultrasonography. Patients with EGPA had 20% higher serum level of VCAM-1 (p < 0.001) and 41.9% of thrombomodulin (p < 0.001). They also had 38.8% lower relative increase of FMD (FMD%) (p < 0.001), indicating endothelial dysfunction. These differences remained significant also after adjustment for potential confounders. Laboratory and ultrasonographic parameters of endothelial injury were correlated to the markers of inflammation and impaired kidney function. Determinants of lower FMD% in a simple regression model were pack-years of smoking (β = - 0.3 [95% confidence interval (CI) - 0.5 to - 0.1]), serum level of IL-6 (β = - 0.36 [95% CI - 0.62 to - 0.1]), and thrombomodulin (β = - 0.34 [95% CI - 0.6 to - 0.08]). EGPA patients are characterized by inflammatory endothelial injury that is likely related to the pathogenesis of the disease. Proper immunosuppressive treatment is the best method to prevent atherosclerosis and future cardiovascular events, the patients may also benefit from additional preventive interventions.

show abstract

Development of Churg‑Strauss syndrome with severe multiple mononeuropathy after leukotriene receptor antagonist treatment in one of the monozygotic twins with asthma

Cited by 4 publications

References 0 publications

Genetic Basis of Myocarditis: Myth or Reality?

Genetic Basis of Myocarditis: Myth or Reality?

Antileukotriene drugs in the treatment of asthma

Endothelial dysfunction in patients with eosinophilic granulomatosis with polyangiitis

Contact Info

Product

Resources

About